期刊文献+

噬菌体展示肽库筛选VPAC1高亲和力结合多肽 被引量:1

Screening of a high-affinity peptide specific for VPAC1 from phage display peptide library
下载PDF
导出
摘要 目的通过噬菌体展示肽库技术筛选VPAC1高亲和力结合十二肽配体,并进行特异性和亲和力鉴定。方法建立稳定表达VPAC1的真核细胞系;利用噬菌体肽库展示技术进行全细胞差减筛选,随机挑取40个噬菌体克隆进行测序,初步鉴定确定阳性克隆,明确外源十二肽序列,固相合成该十二肽;利用体外竞争结合ELISA及流式细胞分析,鉴定目标多肽与VPAC1受体结合的特异性及亲和力。结果成功构建稳定表达VPAC1细胞系;经过4轮差减筛选,回收噬菌体逐轮得到富集,随机挑取40个克隆测序,共得到15条序列不同的多肽,经ELISA鉴定有7个克隆与细胞有特异性高结合能力;阳性噬菌体克隆与细胞结合通过多肽VP1介导;VP1能特异高亲和地与VPAC1受体结合。结论通过噬菌体展示肽库技术成功筛选得到与VPAC1高亲和力特异结合十二肽。 Objective To screen a high-affinity peptide specific for vasoactive intestinal peptide receptor VPAC1 using phage display peptide library,and to identify the specificity and affinity of the selected peptide.Methods A eukaryotic cell line stably expressing VPAC1 was established,four-round subtractive panning using phage display peptide library was conducted,and then forty phage clones were randomly picked out for sequencing.The positive phage clones were identified using cellular ELISA,and exogenous dodecapeptide was determined and synthesized.In vitro competitive binding analysis and flow cytometry were performed to evaluate the binding specificity and affinity of target dodecapeptide.Results VPAC1 was stably expressed on transfected CHO-K1/VPAC1 cells.A significant enrichment was obtained through four rounds of panning,and fifteen different peptide sequences were identified from forty clones.Seven phage clones had specific and high affinity binding with positive cells through cellular ELISA analysis.The positive phage clones bound to CHO-K1/VPAC1 through candidate peptide VP1,and VP1 could specifically bind to VPAC1.Conclusion A high-affinity dodecapeptide specific for VPAC1 is obtained using phage display peptide library.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2013年第1期10-14,共5页 Journal of Third Military Medical University
基金 北京师范大学放射性药物教育部重点实验室开放基金(120204)~~
关键词 VPAC1 稳定转染 噬菌体展示肽库 十二肽 分子探针 VPAC1 stable transfection phage displayed peptide library dodecapeptide molecular probe
  • 相关文献

参考文献16

  • 1Muller J M,Debaigt C,Goursaud S. Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM:an update[J].Peptides,2007,(09):1655-1666.doi:10.1016/j.peptides.2007.04.006.
  • 2Valdehita A,Bajo A M,Fernandez-Martinez A B. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer[J].Peptides,2010,(11):2035-2045.
  • 3Valdehita A,Carmena M J,Collado B. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells[J].Regulatory Peptides,2007,(1/3):101-108.
  • 4Reubi J C,Laderach M,Waser B. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin[J].Cancer Research,2000,(11):3105-3112.
  • 5Rao P S,Thakur ML,Pallela V. 99Tcm labeled VIP analog:evaluation for imaging colorectal cancer[J].Nuclear Medicine and Biology,2001,(04):445-450.doi:10.1016/S0969-8051(01)00205-0.
  • 6Kothari K,Prasad S,Korde A. 99Tcm(CO)3-VIP analogues:preparation and evaluation as tumor imaging agent[J].Applied Radiation and Isotopes,2007,(04):382-386.
  • 7Cheng D F,Yin D Z,Zhang L. Preparation of the novel fluorine-18-1abeled VIP analog for PET imaging studies using two different synthesis methods[J].Journal of Fluorine Chemistry,2007,(03):196-201.doi:10.1016/j.jfluchem.2006.12.007.
  • 8Jemal A,Siegel R,Ward E. Cancer statistics 2009[J].CA:A Cancer Journal for Clinicians,2009,(04):225-249.
  • 9Zhang B,Zhang Y,Wang J. Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library[J].Molecular Medicine,2007,(5/6):246-254.
  • 10Virgolini I,Yang Q,Li S. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors[J].Cancer Research,1994,(03):690-700.

同被引文献10

  • 1Reubi J C, Laderach U, Waser B, et al. Vasoactive intesti- nal peptide/pituitary adenylate cyclase-activating peptide re- ceptor subtypes in human tumors and their tissues of origin [J]. Cancer Res, 2000, 60(11): 3105-3112.
  • 2Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors [ J]. Cancer Res, 1994, 54 (3) : 690 - 700.
  • 3Tang B, Yong X, Xie R, et al. Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review) [J]. Int J Oncol, 2014, 44(4) : 1023 - 1031. DOI: 10.3892/ijo. 2014.2276.
  • 4Moody T W, Nuche-Berenguer B, Jensen R T. Vasoactive in- testinal peptide/pituitary adenylate cyclase activating polypep- tide, and their receptors and cancer[ J ]. Curt Opin Endocri- nol Diabetes Obes, 2016, 23(1) : 38 -47. DOI: 10. 1097/ MED. 0000000000000218.
  • 5Thakur M L, Zhang K, Berger A, et al. VPAC1 receptors for imaging breast cancer: a feasibility study [ J ]. J Nucl Med, 2013, 54 (7) : 1019 - 1025. DOI: 10. 2967/jnumed. 112. 114876.
  • 6Tang B, Li Z, Huang D, et al. Screening of a specific pep- tide binding to VPAC1 receptor from a phage display peptide library[J]. PLoS One, 2013, 8(1): eSd264. DOI: 10. 1371/journal. pone. 0054264.
  • 7Johnbeck C B, Knigge U, Kjaer A. PET tracers for soma- tostatin receptor imaging of neuroendoerine tumors: current status and review of the literature [ J ]. Future Oneol, 2014, 10(14) : 2259 -2277. DOI:10.2217/fon. 14. 139.
  • 8Fani M, Maecke H R. Radiopharmaceutical development of radiolabelled peptides [ J ]. Eur J Nucl Med Mol Imaging, 2012, 39 (Suppl 1 ) : Sll - $30. DOI: 10. 1007/s00259- 011- 2001 -z.
  • 9Hessenius C, Bader M, Meinhold H, et al. Vasoactive in- testinal peptide receptor scintigraphy in patients with pancre- atic adenocarcinomas or neuroendocrine tumours [ J ]. Eur J Nucl Med, 2000, 27 (11) : 1684 - 1693. DOI: 10. 1007/ s002590000325.
  • 10查林,冯世斌,郑磊,黄定德,罗朝学,陈杰,谢来平,厉红民,李前伟.整合素α_vβ_3放射性配体^(99)Tc^m-TP1326的制备及其正常兔显像研究[J].第三军医大学学报,2012,34(3):235-238. 被引量:6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部